Fundraising Fox
Pliant Therapeutics
NASDAQ: PLRXSouth San Francisco, US · Founded 2015 · Delaware corporation · 90 employees on LinkedIn · 3 known investors
Find your way into Pliant Therapeutics
850 people in our graph can introduce you to the Pliant Therapeutics team.
Sign up to see every warm intro you have to Pliant Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Pliant Therapeutics team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Pliant Therapeutics is a clinical-stage biopharmaceutical company developing integrin-based therapeutics to treat serious diseases. The company focuses on understanding integrin biology and molecular mechanisms of pathology to create safer and more effective therapies for patients.
Founders & leadership
Pliant Therapeutics was founded in 2015 by Bernard Coulie.
JH
Johannes HullExecutive
KC
Keith CummingsChief Financial OfficerKeith Cummings holds an MD/MBA from Duke University and has worked as an investment banker at Barclays and Citi covering healthcare and biotech M&A transactions before becoming CFO of Pliant Therapeutics in 2018. He currently leads financing strategy for the clinical-stage biopharmaceutical company.
LC
Lily CheungChief Human Resources OfficerShe brings over 25 years of HR leadership experience across pharmaceutical and technology sectors, including building and scaling shared services functions.
Board
KR
Kevin RaidyBoard director
NE
CH
SB
Suzanne BruhnBoard director
JC
John CurnutteBoard director
HH
Hoyoung HuhBoard director
Investors · 3
Menlo Ventureslisted by Menlo VenturesSan Francisco · $1M – $20M
How we know: Menlo Ventures's portfolio page · the VCSheet dataset · Not right? Tell us
Agent CapitalreportedWaltham
How we know: the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$162.6M disclosed across 2 rounds · 2018–2019
▶$100.4MraisedMar 2020 · 66 investors · BiotechnologyRule 506(b)
▶$100.4MraisedMar 2020 · 66 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Bernard CoulieExecutive Officer, Director
- Barbara HowesExecutive Officer
- Keith CummingsExecutive Officer
- Gayle CrowellDirector
- Smital ShahDirector
- Kevin RaidyDirector
- Charles HomcyDirector
- Neil ExterDirector
- John CurnutteDirector
- Suzanne BruhnDirector
- Hoyoung HuhDirector
- Eric LefebvreExecutive Officer
- Johannes HullExecutive Officer
- Offering amount
- $100.4M
- Amount sold
- $100.4M
- First sale
- Dec 2019
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$62.1MraisedJul 2018 · 29 investors · BiotechnologyRule 506(b)
▶$62.1MraisedJul 2018 · 29 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kevin RaidyDirector
- Suzanne BruhnDirector
- Johannes HullExecutive Officer
- John CurnutteDirector
- Hoyoung HuhDirector
- Neil ExterDirector
- Bernard CoulieExecutive Officer, Director
- Eric LefebvreExecutive Officer
- Charles HomcyDirector
- Offering amount
- $62.1M
- Amount sold
- $62.1M
- First sale
- Jul 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Simply Wall StSimply Wall St is an investment platform that provides financial data visualization and analysis tools for individual investors. The platform serves long-term investors globally by simplifying complex market information into visual and narrative formats to make stock investing more accessible.
Companies working in the same space as Pliant Therapeutics.
Frequently asked questions
- What does Pliant Therapeutics do?
- Pliant Therapeutics is a clinical-stage biopharmaceutical company developing integrin-based therapeutics to treat serious diseases. The company focuses on understanding integrin biology and molecular mechanisms of pathology to create safer and more effective therapies for patients.
- Who founded Pliant Therapeutics?
- Pliant Therapeutics was founded by Bernard Coulie in 2015.
- Who are Pliant Therapeutics's investors?
- Pliant Therapeutics's investors include Menlo Ventures, Agent Capital, Third Rock Ventures.
- How much funding has Pliant Therapeutics raised?
- Pliant Therapeutics has disclosed $162.6M raised across 2 rounds.
- Where is Pliant Therapeutics headquartered?
- Pliant Therapeutics is headquartered in South San Francisco, US.